血液恶性肿瘤患者侵袭性曲霉病的无创诊断:一项前瞻性诊断准确性研究
该研究前瞻性纳入138例血液恶性肿瘤高危患者的148次临床发作,评估尿液三乙酰基夫沙林C/肌酐(uTafC/Cr)、血清半乳甘露聚糖(sGM)和血清五聚素-3(sPtx3)无创组合对侵袭性曲霉病(IA)的诊断准确性。uTafC/Cr或sGM在对照中无假阳性,各检出51.4%的IA发作;加用sPtx3将检出率提高至83.8%,但特异性降低。
要点
- uTafC/Cr或sGM可作为以曲霉为重点的无创辅助诊断,对照中无假阳性。
- uTafC/Cr与sGM各检出51.4%的IA发作,加用sPtx3后检出率升至83.8%。
- sPtx3单独敏感性70.3%、特异性58.3%,联合后特异性降至57.6%。
核心结论
- uTafC/Cr或sGM可作为基于BALF检测的无创辅助手段,sPtx3提高检出率但特异性有限,需前瞻性验证。
研究设计与样本
- 前瞻性诊断准确性研究,纳入138例血液恶性肿瘤高危患者的148次临床发作,其中37次为确诊/临床诊断IA,111次为对照。
主要发现
- sGM和uTafC/Cr在可用对照发作中无假阳性(sGM 0/98;uTafC/Cr 0/111),各检出51.4%(19/37)的IA发作。
- sPtx3单独敏感性70.3%(26/37),特异性58.3%(21/36)。
- 联合sPtx3后检出率升至83.8%(31/37),但在完整病例对照亚组中特异性为57.6%(19/33)。
- 在±72小时配对窗口分析中,BALF真菌学(GM、PCR和/或培养)在19/23例受检IA发作中阳性(82.6%;95% CI,62.9-93.0%)。
- TafC在4°C稳定,LC-MS较MALDI-MS分析灵敏度更高。
关键数值与推荐
- sGM和uTafC/Cr采用预设 cut-off;sPtx3阳性界值由ROC曲线导出。
- uTafC/Cr通过液相色谱-质谱(LC-MS)定量;sGM和sPtx3通过酶免疫分析检测。
临床怎么用
- 对于血液恶性肿瘤高危患者,可考虑uTafC/Cr或sGM作为无创辅助诊断工具,但需结合BALF等确诊手段。
- sPtx3联合可提高检出率,但因其特异性有限,阳性结果需谨慎解读并进一步验证。
局限性
- sPtx3需前瞻性验证;完整病例对照亚组中联合策略特异性较低。
- 研究为单中心(Leuven,2018-2021),样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate a non-invasive panel integrating urinary triacetylfusarinine C normalised to creatinine (uTafC/Cr), serum galactomannan (sGM) and serum pentraxin-3 (sPtx3) for detection of invasive aspergillosis (IA) in patients with haematological malignancies. METHODS: Prospectively collected urine and serum from 148 clinical episodes in 138 high-risk patients with haematological malignancies (Leuven, 2018-2021) were analysed in a diagnostic accuracy study (37 proven/probable IA episodes from 37 patients; 111 control episodes from 104 patients). Median sampling days relative to the diagnostic reference day (day 0) were +1 for urine uTafC/Cr, 0 for sGM and +2 for sPtx3. uTafC/Cr was quantified by liquid chromatography-mass spectrometry (LC-MS); sGM and sPtx3 by enzyme immunoassays. Prespecified cut-offs were used for sGM and uTafC/Cr; sPtx3 positivity was receiver operating characteristic-derived. Analytical TafC stability and the relative analytical sensitivity of LC-MS and MALDI-MS were assessed in validation experiments. RESULTS: sGM and uTafC/Cr showed no false positives in available control episodes (sGM, 0/98; uTafC/Cr, 0/111) and each detected 51.4% of IA episodes (19/37). sPtx3 alone showed sensitivity of 70.3% (26/37) and specificity of 58.3% (21/36). Adding sPtx3 to the uTafC/Cr or sGM pair increased case detection to 83.8% (31/37), with lower specificity in the complete-case control episode subset (57.6%; 19/33 control episodes). In a ±72 h paired-window analysis, bronchoalveolar lavage fluid (BALF) mycology, defined as BALF GM, Aspergillus PCR and/or fungal culture, was positive in 19/23 tested IA episodes (82.6%; 95% CI, 62.9-93.0%). TafC was stable at 4 °C, and LC-MS was more sensitive than MALDI-MS. CONCLUSIONS: uTafC/Cr or sGM provides an Aspergillus-focused non-invasive adjunct to BALF-based testing; sPtx3 increased case detection but had limited specificity and requires prospective validation.
引用
- Patil RH, Dobiáš R, Vanbiervliet Y, et al. Non-invasive diagnosis of invasive aspergillosis in patients with haematological malignancies: a prospective diagnostic accuracy study. Clin Microbiol Infect. 2026. PMID: 42858895. doi:10.1016/j.cmi.2026.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。